Although our study showed that the average SAV1 immunoreactivity was increased in the CRC tissue compared to the non-cancerous large intestine tissue, we observed a reduced SAV1 protein immunoreactivity in the tumor tissues from the patients with worse clinicopathological parameters. This evidence concerns the gene SAV1 and colorectal carcinoma.